| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 01/22/2009 | US20090023654 Axmi-008, a delta-endotoxin gene and methods for its use |
| 01/22/2009 | US20090023653 Method of using broad-spectrum delta-endotoxins |
| 01/22/2009 | US20090023652 Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders |
| 01/22/2009 | US20090023651 Inhibitors of human plasmin derived from the kunitz domains |
| 01/22/2009 | US20090023649 for treating diseases relating to angiogenesis; fusion protein possesses ribosome inactivating activity and ability to bind to cellular vascular endothelial growth factor (VEGF) receptors |
| 01/22/2009 | US20090023648 Methods for Treating Body Tissue |
| 01/22/2009 | US20090023647 Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
| 01/22/2009 | US20090023646 GHRH analogues |
| 01/22/2009 | US20090023645 AIB1, a novel steroid receptor co-activator |
| 01/22/2009 | US20090023636 Methods and compositions for the prevention and treatment of anemia |
| 01/22/2009 | US20090023635 Factor VII or VIIa - Like Molecules |
| 01/22/2009 | US20090023632 Hemoglobin-haptoglobin complexes |
| 01/22/2009 | US20090023627 Compositions and methods for alzheimer's disease |
| 01/22/2009 | US20090023602 Binding polypeptides with restricted diversity sequences |
| 01/22/2009 | US20090023226 Variant Integrin Polypeptides and Uses Thereof |
| 01/22/2009 | US20090023224 Vascular endothelial growth factor 2 |
| 01/22/2009 | US20090023215 Novel reagents for transfection of eukaryotic cells |
| 01/22/2009 | US20090023207 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS |
| 01/22/2009 | US20090023185 Avidin Mutants |
| 01/22/2009 | US20090023184 Novel Tachykinin Peptides, Precursor Peptides Thereof And Genes Encoding The Same |
| 01/22/2009 | US20090023183 Method For Preparing Recombinant Peptide From Spider Venom and Analgesic Composition Containing The Peptide |
| 01/22/2009 | US20090023164 Compositions and methods for the detection of hiv-1/hiv-2 infection |
| 01/22/2009 | US20090023160 Antibodies specific for CYP1B1 |
| 01/22/2009 | US20090023153 Targeted modification of chromatin structure |
| 01/22/2009 | US20090023152 Transcription factor MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 01/22/2009 | US20090022873 Genes Useful for the Industrial Production of Citric Acid |
| 01/22/2009 | US20090022776 Composition and method for treatment and prevention of restenosis |
| 01/22/2009 | US20090022762 Polyvalent influenza virus-like particle (VLP) compositions |
| 01/22/2009 | US20090022756 Recombinant F1-V Plague Vaccine |
| 01/22/2009 | US20090022754 Construction of recombinant immunodominant Rickettsia typhi proteins; using methylated or unmethylated recombinant OmpB fragments in immunoassays for detection of exposure to Rickettsia typhi |
| 01/22/2009 | US20090022753 Surface proteins of streptococcus pyogenes |
| 01/22/2009 | US20090022748 Unique associated Kaposi's sarcoma virus sequences and uses thereof |
| 01/22/2009 | US20090022747 B7-h3 and b7-h4, novel immunoregulatory molecules |
| 01/22/2009 | US20090022743 Peptides Effective in the Treatment of Tumors and Other Conditions Requiring the Removal or Destruction of Cells |
| 01/22/2009 | US20090022742 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 01/22/2009 | US20090022725 antagonist antibody that blocks binding of IL-17; degenerative cartilaginous disorders and other inflammatory diseases |
| 01/22/2009 | US20090022724 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 01/22/2009 | US20090022720 Conjugate of an antibody against CD4 and antifusogenic peptides |
| 01/22/2009 | US20090022718 Methods of treating a blood pathology using anti-TNF antibodies and fragments thereof |
| 01/22/2009 | US20090022716 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022714 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022713 Anti-pro87299 antibodies |
| 01/22/2009 | US20090022710 Nuclear factor of activated t cells receptor |
| 01/22/2009 | US20090022709 Control of sorbose utilization genes and uses thereof |
| 01/22/2009 | US20090022708 Trefoil Factors and Methods of Treating Proliferation Disorders Using Same |
| 01/22/2009 | US20090022704 Method for the treatment of gout or pseudogout |
| 01/22/2009 | US20090022702 Methods for introducing mannose 6-phosphate and other oligosacharides onto glycoproteins |
| 01/22/2009 | US20090022657 Novel CXCL8 antagonists |
| 01/22/2009 | US20090022656 Lipidated glycoprotein particles and methods of use |
| 01/22/2009 | CA2789123A1 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
| 01/22/2009 | CA2789112A1 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
| 01/22/2009 | CA2729011A1 Varicella zoster virus-virus like particles (vlps) and antigens |
| 01/22/2009 | CA2693956A1 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant |
| 01/22/2009 | CA2693899A1 Chimeric varicella zoster virus-virus like particles |
| 01/22/2009 | CA2693712A1 Methods and compositions for treating brain diseases |
| 01/22/2009 | CA2693154A1 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
| 01/22/2009 | CA2693137A1 Engineered scfv against bovine herpes virus type i |
| 01/22/2009 | CA2693051A1 Lantibiotic-based compounds having antimicrobial activity |
| 01/22/2009 | CA2692826A1 An anti-cancer cytotoxic monoclonal antibody |
| 01/22/2009 | CA2692650A1 Transgenic plants with increased stress tolerance and yield |
| 01/22/2009 | CA2692612A1 Purification of pegylated polypeptides |
| 01/22/2009 | CA2691406A1 Preprocalcitonin antigen t epitopes |
| 01/22/2009 | CA2691127A1 Phosphorylation of histone h3 at threonine 11 - a novel epigenetic mark for transcriptional regulation |
| 01/21/2009 | EP2017621A1 Phosphorylation of histone H3 at threonine 11 - a novel epigenetic mark for transcriptional regulation |
| 01/21/2009 | EP2017345A1 Nucleotide sequences and polypeptides encoded thereby useful for inreasing plant size and increasing the number and size of leaves |
| 01/21/2009 | EP2017343A2 Protein A based binding domains with desirable activities |
| 01/21/2009 | EP2017342A1 Recombinant allergen with reduced enzymatic activity |
| 01/21/2009 | EP2017341A2 Apo-2 ligand |
| 01/21/2009 | EP2017337A1 Human tumor necrosis factor receptors |
| 01/21/2009 | EP2017336A1 Marker for selecting aphanomyces cochlioides-resistant variety and selection method therefor |
| 01/21/2009 | EP2017288A1 Protease stabilized, pegylated insulin analogues |
| 01/21/2009 | EP2017287A2 Method of producing hydroxyalkyl starch derivatives |
| 01/21/2009 | EP2017286A2 Transporter genes |
| 01/21/2009 | EP2017285A1 Antimicrobial linear peptides |
| 01/21/2009 | EP2017284A1 New polypeptides inducing apoptosis and uses thereof |
| 01/21/2009 | EP2016953A2 Vascular endothelial cell growth factor antagonists and uses thereof |
| 01/21/2009 | EP2016951A1 Polypeptides homologous to VEGF and BMP1 |
| 01/21/2009 | EP2016950A1 Pharmaceutical composition comprising an exedin-4 peptide |
| 01/21/2009 | EP2016420A1 HlSTONES |
| 01/21/2009 | EP2016419A2 Methods for the in vitro screening of compounds inhibiting production of infectious hiv-1 virions |
| 01/21/2009 | EP2016102A2 Chimeric t cell receptors and related materials and methods of use |
| 01/21/2009 | EP2016098A1 Antibody-targeted cytokines for therapy |
| 01/21/2009 | EP2016097A2 Methods and compositions relating to zpa polypeptides |
| 01/21/2009 | EP2016096A2 Proder p 1 expressed in a prokaryotic cell |
| 01/21/2009 | EP2016095A2 Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
| 01/21/2009 | EP2016093A1 Peptides for use in diagnosing the presence of ruptured atherosclerotic lesions in an individual |
| 01/21/2009 | EP2016089A1 Gene defects and mutant alk kinase in human solid tumors |
| 01/21/2009 | EP2015776A1 Glp-1 compound/glucagon antibody compositions |
| 01/21/2009 | EP2015770A2 Insulin derivative |
| 01/21/2009 | EP2015760A1 Use of cells containing a specific dna molecule as cytopathic agents to inhibit the proliferation of cells |
| 01/21/2009 | EP1934606A4 Optimized trpm8 nucleic acid sequences and their use in cell based assays and test kits to identify trpm8 modulators |
| 01/21/2009 | EP1909559A4 Management of plant pathogens |
| 01/21/2009 | EP1851239B1 Replication-deficient rna viruses as vaccines |
| 01/21/2009 | EP1846769B1 Porcine intrinsic factor |
| 01/21/2009 | EP1569680B1 Treatment of diabetes |
| 01/21/2009 | EP1506228B1 Role of p62 in aging-related disease |
| 01/21/2009 | EP1497323B1 Multiple branch peptide constructions comprising from 2 to 16 branches of the peptide rqgys or from 8 to 16 branches of the peptide rqgy providing from the hiv gp41 glycoprotein |
| 01/21/2009 | EP1495330B1 Method of identifying transmembrane protein-interacting compounds |
| 01/21/2009 | EP1487867B1 Modified plasminogen activator inhibitor type-1 and methods based thereon |
| 01/21/2009 | EP1432443B1 Angiotensin peptide-carrier conjugates and uses thereof |